Journal: Frontiers in Molecular Neuroscience

Article Title: Repeated inhibition of sigma-1 receptor suppresses GABA A receptor expression and long-term depression in the nucleus accumbens leading to depressive-like behaviors

doi: 10.3389/fnmol.2022.959224

Figure Lengend Snippet: Involvement of impaired LTD in the NAc in depressive-like behaviors. (A – C) Bar graphs show the distance traveled in OFT, and the immobility time in FST and in TST of control mice, NE-100 mice, and mice treated with NAc-injection of quinpirole (quin), PMA, or muscimol (mus). ** p < 0.01 vs. control mice; # p < 0.05 vs. vehicle-treated NE-100 mice ( n = 11 mice of quin-treated group in FST, n = 11 mice of vehicle-treated control group and PMA-treated control group in TST, and n = 12 mice in the other groups; two-way ANOVA).

Article Snippet: σ 1 R antagonist NE-100 (Tocris Cat#3133), PKC activator phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich Cat#P1585), PKC inhibitor GF109302X (Tocris Cat#0741), D2R antagonist L-sulpiride (Sigma-Aldrich Cat#S7771), D2R agonist quinpirole (Sigma-Aldrich Cat#Q102), GABA A R agonist muscimol (Alomone Labs Cat#M-240), GABA A R antagonist bicuculline(Sigma-Aldrich Cat#14340), D1R agonist SKF38393 (Sigma-Aldrich Cat#S101), D1R antagonist SCH23390 (TocrisCat#No.

Techniques: Injection

Journal: Frontiers in Molecular Neuroscience

Article Title: Repeated inhibition of sigma-1 receptor suppresses GABA A receptor expression and long-term depression in the nucleus accumbens leading to depressive-like behaviors

doi: 10.3389/fnmol.2022.959224

Figure Lengend Snippet: Repeated injection of NE-100 leads to synaptic dysfunction. (A) The timecourse of the experimental procedure. (B) Schematic illustrating sites of stimulating electrode (Stim) and recording electrode (Rec) in the shell of NAc (left panel). The right panel shows a typical trace. The dark mark of the initial descending phase indicates the 10% to 90% data points of the slope, and the two-way arrow indicates the duration. (C) Input-output (I-O) curve in the NAc. Each point represents the group mean value of fEPSP slopes against stimulus intensity from 0.1 mA to 1.1 mA in control mice and NE-100 mice. Representative traces of fEPSP evoked at 0.5 mA stimulus intensity in control mice and NE-100 mice ( n = 8 slices/4 mice per group; repeated-measures ANOVA). (D) Bar graphs show the duration (ms) of fEPSP in control mice and NE-100 mice. ** p < 0.01 vs. control mice ( n = 8 slices/4 mice per group; Student’s- t test). (E) PPR (%) of fEPSP slopes was plotted against interpulse intervals (IPIs) ranging from 15 ms to 100 ms. Traces represent fEPSPs evoked by stimulation pulses delivered with a 25 ms IPI. * p < 0.05 vs. control mice ( n = 8 slices/4 mice per group; repeated-measures ANOVA). (F) LTD induction by delivering low-frequency stimulation (LFS) in control mice and NE-100 mice. A solid line indicates when LFS was given. Traces show fEPSPs pre- and post-LFS. ** p < 0.01 vs. control mice ( n = 8 slices/4 mice per group; Mann-Whitney U test). (Gi,Gii) Bar graphs show the duration (ms) of fEPSP and the PPR value (25 ms IPI) in vehicle-treated and bicuculline (bicu)-treated control mice. ** p < 0.01 vs. vehicle-treated mice ( n = 8 slices/4 mice per group; Student’s t -test). (H) LTD induction by LFS in slices of control mice treated with bicuculline (bicu). ** p < 0.01 vs. vehicle-treated mice ( n = 8 slices/4 mice per group; Mann-Whitney U test). (Ii,Iii) Bar graphs show the duration (ms) of fEPSP and the PPR value (25 ms IPI) in vehicle-treated and muscimol (mus)-treated NE-100 mice. ** p < 0.01 vs. vehicle-treated mice ( n = 8 slices/4 mice per group; Student’s t -test). (J) LTD induction in slices of NE-100 mice treated with muscimol (mus). ** p < 0.01 vs. vehicle-treated mice ( n = 8 slices/4 mice per group; Mann-Whitney U test).

Article Snippet: σ 1 R antagonist NE-100 (Tocris Cat#3133), PKC activator phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich Cat#P1585), PKC inhibitor GF109302X (Tocris Cat#0741), D2R antagonist L-sulpiride (Sigma-Aldrich Cat#S7771), D2R agonist quinpirole (Sigma-Aldrich Cat#Q102), GABA A R agonist muscimol (Alomone Labs Cat#M-240), GABA A R antagonist bicuculline(Sigma-Aldrich Cat#14340), D1R agonist SKF38393 (Sigma-Aldrich Cat#S101), D1R antagonist SCH23390 (TocrisCat#No.

Techniques: Injection, MANN-WHITNEY